@article {1586141,
	title = {Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy},
	journal = {Semin Ophthalmol},
	volume = {36},
	number = {4},
	year = {2021},
	month = {2021 May 19},
	pages = {329-334},
	abstract = {Chimeric antigen\&nbsp;receptor (CAR) T-cell therapy is a revolutionary addition to the burgeoning field of immunotherapy. CAR T-cells are engineered by combining a T-cell receptor with the antigen-binding site of an immunoglobulin that allows the hybrid cell to target antigens of interest. CAR T-cell therapy has been approved to treat various hematologic malignancies, including relapsed or refractory B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. While the treatment efficacy is exciting, challenges remain in understanding the unique spectrum of adverse effects of CAR T-cell therapy, including cytokine release syndrome and neurotoxicity. Innovative research is underway to expand this therapy into solid tumors and fields beyond hematology and oncology. To date, there has been limited research into ophthalmic uses and considerations of CAR T-cell therapy. This review focuses on preclinical investigations into CAR T-cell therapy for retinoblastoma and uveal melanoma, as well as ophthalmic complications of CAR T-cell therapy.},
	issn = {1744-5205},
	doi = {10.1080/08820538.2021.1897857},
	author = {Chodnicki, Kevin D and Prasad, Sashank}
}
